Eli Lilly vs Novo Nordisk

The Battle

Welcome back to Battle Stocks, where we put two companies in the same ring and let the numbers decide. This week is the headline fight of the entire drug industry: the two firms that created the GLP-1 era and now own a duopoly that one Wall Street estimate sees reaching $150 billion in annual sales by 2030. Eli Lilly with tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity. Novo Nordisk with semaglutide, sold as Ozempic and Wegovy.

A year ago this would have been a close fight. It is not close anymore, at least not on the business. Lilly has pulled decisively ahead on growth, share, and pipeline, while Novo has spent the last year absorbing a string of setbacks that erased more than $400 billion of market value from its 2024 peak. So why is this still interesting? Because the market knows all of that, and has priced the two stocks accordingly. The question that actually matters is not which company is winning. It is whether the price you pay for the winner leaves anything on the table, and whether the discount on the loser is an opportunity or a warning.

The Tale of the Tape

Start with the most recent quarter, the first quarter of 2026, because it captures the divergence in a single snapshot.

Read those two boxes back to back and the fight is essentially over on the fundamentals. One company is compounding at a rate almost unheard of at its size. The other is managing a decline while it waits for new products to stabilize the base. Everything that follows is about whether the stock prices already reflect that, and they largely do.

The Case for Eli Lilly

The bull case for Lilly is that it is winning on every axis that matters in this market at the same time. On efficacy, tirzepatide remains the most effective approved medicine in the category. On share, Lilly now holds roughly 60% of the U.S. GLP-1 market by some measures, and it is still taking ground. On profitability, gross margin runs near 82% and first-quarter net income roughly doubled.

The pipeline is where the lead widens. In April the FDA approved Foundayo (orforglipron), the first oral small-molecule GLP-1 for obesity. The small-molecule part is the strategic point: unlike a peptide pill, it is far easier and cheaper to manufacture at the scale of tens of millions of patients, which is the bottleneck that has defined this entire market. In a head-to-head diabetes study, orforglipron beat oral semaglutide on both blood sugar and weight loss. Behind it sits retatrutide, a triple-acting drug that has already posted strong late-stage results in both diabetes and osteoarthritis. Lilly is not just leading today. It is leading the next two product cycles.

The honest counterweight, stated up front because that is what this brand does, is the price. At roughly 40 times trailing earnings and about 31 times forward guidance, with a dividend yield of only about 0.6%, Lilly is valued as the dominant franchise it is. There is very little room in that multiple for disappointment. Realized prices already fell 13% in the quarter as pricing deals took hold, and the entire investment case assumes volume keeps outrunning price for years. Lilly is the better company by a wide margin. It is not a cheap stock, and it is not pretending to be.

The Case for Novo Nordisk

The case for Novo is not that it is the better business. It plainly is not, at least right now. The case is that the stock has fallen so far that a merely stabilizing business could still be a rewarding investment. Novo trades around 10 times trailing earnings, pays a dividend yield near 4%, and carries a beta of just 0.35, meaning it has moved far less than the market. After a decline of roughly 40% over the past year, a great deal of bad news is already in the price.

And there is a real bright spot. The Wegovy pill, launched in the United States in January, has become what the company calls the strongest GLP-1 volume launch in U.S. history, surpassing 3 million prescriptions within months. Novo still holds roughly a third of the global branded diabetes market, a franchise that does not evaporate quickly. It retains pricing power in international markets, and it has begun reshaping itself, with a new chief executive and a partnership with OpenAI aimed at drug discovery. For an investor who believes the GLP-1 market is large enough for two winners, paying ten times earnings for the number two player is a very different proposition than paying forty for the leader.

The counterweight here is heavier than the bulls admit. The company is guiding to a declining year. Its next-generation obesity drug, CagriSema, failed to beat Lilly's Zepbound in a closely watched trial, which is precisely the kind of setback that justifies a low multiple rather than contradicting it. Ozempic pricing in the United States is still eroding at 10% to 15% a year. Cheap can stay cheap for a long time when earnings are falling, and the line between a value opportunity and a value trap is drawn by whether the decline actually stops.

What Actually Separates Them

Both companies enjoy enormous moats: patent-protected blockbusters, manufacturing scale that took years and billions to build, and brands that doctors and patients ask for by name. But the moats are not equally durable, and the difference is the heart of this battle.

Lilly's advantage is that its moat is widening in the two places that decide the next decade: manufacturing and pipeline. The constraint in GLP-1 has never really been demand. It has been the ability to make enough drug. A small-molecule oral like orforglipron attacks that constraint directly, because it can be produced more like a conventional pill than a delicate peptide. Pair that with a deeper next-generation pipeline, and Lilly controls more of the ways this market can evolve.

Novo's moat is real but currently on the defensive. Its peptide expertise and its decades-long diabetes franchise are genuine assets, and the Wegovy pill proves it can still launch at scale. But a failed next-generation candidate and a leadership transition are signs of a company defending its position rather than extending it. The same regulatory wave matters to both: the most-favored- nation pricing deals and the new Medicare obesity coverage that begins in mid-2026 will compress price while expanding the covered population by tens of millions. That combination rewards whoever can supply the most volume at the lowest unit cost, which points back to Lilly's scalable pill.

What the Wealth Engine Scores Say

Before the valuation verdict, here is what the Wealth Engine Pro platform's systematic scoring shows for both stocks right now. This is the most interesting part of the matchup, because the scores do not line up the way the headlines do.

Read that twice. The platform rates the two businesses almost identically on quality, with Novo a hair higher on Company Strength at 70 versus 69. But on valuation and outlook they diverge sharply. Lilly, the obvious winner of the business fight, is flagged Expensive and Neutral, trading roughly 63% above the platform's calculated fair value. Novo, the company losing the fight, is flagged Undervalued with a Bullish outlook. The systematic data is more positive on the loser than on the winner.

A note on Novo's fair value figure. The platform's raw output references the Copenhagen-listed shares, which trade in Danish kroner rather than the U.S. dollar price of the American listing. Converting to dollars, the model puts Novo modestly below fair value, consistent with its low earnings multiple and Bullish rating. We have stated it that way rather than reprint the unconverted number, because a score is only useful if it is accurate.

These scores are systematic. They evaluate companies on reported financials, balance sheet quality, moat characteristics, and valuation models including discounted cash flow, peer comparison, and earnings power. They measure what a company is today, not what it might become. That is by design, to keep emotion and forward speculation out of the numbers.

This article is doing something different. It is making an editorial argument about the future: that Lilly's manufacturing edge and deeper pipeline justify its lead even though the price is steep, and that Novo's cheapness is real but comes attached to a business that is still shrinking. Both perspectives are data. The platform tells you Lilly is expensive and Novo is cheap. The article tells you why the expensive one is still the better company and why the cheap one carries a reason for its discount. Research either name yourself on the platform and decide which signal matters more for your situation.

The Valuation Verdict

The two valuations describe two completely different bets. Lilly at roughly 31 times forward earnings is a growth bet: you are paying a premium today on the expectation that revenue keeps compounding at double-digit rates and the pipeline keeps producing. Novo at roughly 10 times trailing earnings with a 4% yield is a mean-reversion bet: you are paying a discount on the expectation that the decline flattens and sentiment recovers.

Here is the uncomfortable truth the multiples expose. Lilly is the better company and the worse value. Novo is the worse company and the better value. Neither of those statements cancels the other out, and the mistake most investors make is collapsing them into a single verdict. The platform's fair value estimate says it plainly: even the best business in the industry can be priced past the point where the math works, and even a struggling one can be priced below it. The question is not which stock is cheap. It is which risk you would rather hold.

What Could Go Wrong

A verdict is only honest if it carries the case against it. Here is the steelman on both sides.

The case against Lilly

The single biggest risk is the valuation itself. At 40 times earnings, Lilly has to keep delivering near-perfect results to justify the price, and any one of several things could interrupt that: a faster-than-expected collapse in realized prices as the most-favored-nation deals and Medicare negotiation take hold, a manufacturing or safety stumble on the orforglipron ramp, or simply a market that decides a trillion-dollar drugmaker should not trade at a growth-stock multiple. A great company bought at a stretched price can still be a poor investment. That is the entire risk in one sentence.

The case for Novo, and against this verdict

If you believe the GLP-1 market is genuinely large enough for two dominant players, the Novo discount may be the better risk-reward, and the platform's Bullish rating agrees. The Wegovy pill launch proves the franchise can still grow, the diabetes base is durable, the 4% dividend pays you to wait, and a low beta cushions the downside. If Novo merely stops shrinking, a ten-times multiple has substantial room to re-rate, and the contrarian who bought the leader of two years ago at its lows would have done very well. Choosing Lilly is a choice for business quality over statistical cheapness. That is a defensible choice, not an inevitable one.

The Data Picks a Winner

Between the two, the data picks Eli Lilly. It is growing faster, holds more share, earns higher margins, owns the more scalable oral technology, and carries the deeper next-generation pipeline. On every measure of what makes a drug company durable, Lilly is ahead, and the gap is widening rather than closing. If this battle is about which is the better business, there is no real argument. Lilly wins.

But picking the winner is not the same as saying buy it today, and this is where the verdict and the platform agree. Lilly trades around 63% above the fair value our models calculate, at roughly 40 times earnings, with a dividend under 1%. The business deserves to win this matchup. The stock deserves a spot on a watchlist far more than it deserves a purchase at this price. A meaningful pullback, the kind that has hit even the best companies in this volatile category, would turn the clear winner of this battle into a genuine opportunity. Until then, the most useful thing the data does is keep those two ideas separate.

That separation is the whole discipline of Wealth Engine Pro. The narrative says own the GLP-1 leader. The data agrees Lilly is the leader, and then it does the part the narrative skips: it tells you the leader is expensive and the laggard is cheap, and it refuses to pretend that the better company and the better entry price are the same thing. We are comfortable naming Lilly the winner. We are equally comfortable saying we would wait for the price to come to us.